Amicus Therapeutics Gross Profit 2010-2022 | FOLD

Amicus Therapeutics gross profit from 2010 to 2022. Gross profit can be defined as the profit a company makes after deducting the variable costs directly associated with making and selling its products or providing its services.
Amicus Therapeutics Annual Gross Profit
(Millions of US $)
2021 $271
2020 $230
2019 $160
2018 $77
2017 $31
2016 $4
2015 $
2014 $1
2013 $0
2012 $18
2011 $21
2010 $1
2009 $64
Amicus Therapeutics Quarterly Gross Profit
(Millions of US $)
2022-03-31 $71
2021-12-31 $74
2021-09-30 $68
2021-06-30 $69
2021-03-31 $60
2020-12-31 $61
2020-09-30 $59
2020-06-30 $56
2020-03-31 $54
2019-12-31 $48
2019-09-30 $43
2019-06-30 $39
2019-03-31 $30
2018-12-31 $28
2018-09-30 $16
2018-06-30 $18
2018-03-31 $14
2017-12-31 $12
2017-09-30 $9
2017-06-30 $6
2017-03-31 $3
2016-12-31 $2
2016-09-30 $2
2016-06-30
2016-03-31
2015-12-31
2015-09-30
2015-06-30
2015-03-31
2014-12-31
2014-09-30 $0
2014-06-30 $0
2014-03-31 $0
2013-12-31 $0
2013-09-30 $0
2013-06-30
2013-03-31
2012-12-31 $0
2012-09-30
2012-06-30 $11
2012-03-31 $8
2011-12-31 $6
2011-09-30 $6
2011-06-30 $4
2011-03-31 $6
2010-12-31
2010-09-30
2010-06-30
2010-03-31
2009-12-31 $49
2009-09-30 $5
2009-06-30 $5
2009-03-31 $5
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $2.174B $0.306B
Amicus Therapeutics, Inc. is a global patient-centric biotechnology company engaged in the discovery, development and commercialization of a diverse set of novel treatments for patients living with rare metabolic diseases.?The company has one marketed medicine in its portfolio named Galafold which is the first and the only approved oral precision medicine for patients living with Fabry disease, having amenable genetic variants. Migalastat is a potent orally available inhibitor of alpha-Gal A.?The drug was granted an accelerated approval by the FDA for treating adult patients with a confirmed diagnosis of Fabry disease and an amenable genetic variant. Galafold is the first and only oral therapy approved in the EU for the long-term treatment of adolescents with Fabry disease.?The lead pipeline candidate in the company's portfolio is AT-GAA, a differentiated biologic for Pompe disease. The company has one gene-therapy program in its pipeline CLN3, a type of Batten disease, being evaluated in a phase I/II study.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $162.213B 9.87
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.280B 16.23
Biohaven Pharmaceutical Holding (BHVN) United States $10.017B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.593B 0.00
Emergent Biosolutions (EBS) United States $1.775B 7.60
Arcus Biosciences (RCUS) United States $1.357B 34.40
Myovant Sciences (MYOV) United Kingdom $1.000B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.486B 0.00
Gelesis Holdings (GLS) United States $0.360B 0.00
Zymeworks (ZYME) Canada $0.346B 0.00
Ambrx Biopharma (AMAM) United States $0.149B 0.00
Enzo Biochem (ENZ) United States $0.116B 23.80
SQZ Biotechnologies (SQZ) United States $0.099B 0.00